Task Force 4: Clinical Considerations for the Care of Athletes with Genetic Cardiomyopathies.
Researchers
Sabiha Gati, Michael J Ackerman, Aaron L Baggish, Jonathan H Kim, Benjamin D Levine, Martin Maron, Matthew Martinez, Sharlene M Day
Abstract
The updated AHA/ACC Scientific Statement on Clinical Considerations for Competitive Sports Participation for Athletes with Cardiovascular Conditions presents the clinical considerations for athletes with genetic cardiomyopathies, including hypertrophic, dilated, arrhythmogenic, and left ventricular hypertrabeculation. This ACSM Official Pronouncement complements the 2020 ACC/AHA Scientific Statement by providing athlete-specific context, practical guidance for shared decision-making, and genotype-informed risk assessment for competitive sports participation, moving away from blanket sports disqualifications. Sports participation recommendations for each condition are tailored to risk levels, symptomatology, and genotype. Regular follow-ups and close surveillance are advised. This evolving approach underscores the importance of individualized care, ongoing research, and the integration of new data to better inform shared decision-making on the risks and benefits of competitive sports in athletes with cardiomyopathies.Source: PubMed (PMID: 43024813)View Original on PubMed